Sipuleucel-T boosts survival versus abiraterone or enzalutamide alone in real-world mCRPC analysis

[George71]

The immunotherapy was also associated with fewer emergency department visits than either of the androgen pathway receptor inhibitors.

Real-world data showed that use of the immunotherapy sipuleucel-T (Provenge) during any line of treatment in men with metastatic castration-resistant prostate cancer (mCRPC) improved overall survival (OS) versus treatment regimens that included abiraterone acetate (Zytiga) or enzalutamide (Xtandi), but not sipuleucel-T.1,2

The findings from the retrospective analysis, which were published online in Advances in Therapy, showed a 41% reduction in the risk of death among patients who received sipuleucel-T compared with those who received abiraterone or enzalutamide, but not the immunotherapy. The median OS was improved by 14.5 months with sipuleucel-T

urologytimes.com/view/sipul...

[tango65]

Thanks for Posting. This is a link to the full article:

link.springer.com/article/1...

[Life5]

what about hormone sensitive or castration sensitive patients?

[George71 in reply to Life5]

it is a shame but I don't think you can get it until CRPC

[Hidden in reply to Life5]

I received Provenge when i was still castrate sensitive. Medicare covered it.

[George71 in reply to Hidden]

Thanks Fran2020,

what was your status at the time you applied for Provenge -- mets? on regular scans?

[Hidden in reply to George71]

One met on L5 vertebrate, regular bone and ct scan.